A spinout from the University of Osaka is developing a slim, lightweight, single-use endoscope designed specifically for gastric cancer screening. By simplifying conventional endoscope design, the device aims to reduce patient discomfort, lower costs, and lessen the burden on healthcare professionals. Its disposable format removes the need for cleaning and disinfection, while future integration with AI and digital platforms could support more accessible and efficient screening.

Kyoto, Japan -- Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells. Patients with these disorders are also at increased risk of developing myelodysplastic syndromes -- MDS -- a group of blood cancers in which the bone marrow produces excess abnormal blood cells and insufficient healthy ones.

When young patients are diagnosed with either condition, an underlying germline genetic abnormality can generally be suspected as the cause. The genetic basis and mechanisms of these diseases remain unknown in many patients, but advances in genomic analysis are identifying an increasing number of causative genes.

Recently, germline variants in the genes SLF2 and SMC5 were reported to cause Atelis Syndrome, a neurodevelopmental disorder frequently accompanied by blood abnormalities. During a follow-up with syndrome patients, a team of researchers at Kyoto University found that some had developed MDS at a young age, and further that clinical features of IBMFS were evident. The team hypothesized that the abnormalities in SLF2 and SMC5 represent a previously unrecognized cause of IBMFS, and indicate a predisposition to MDS.

Mechanosensitive Piezo ion channels, particularly Piezo1 and Piezo2, are gaining recognition as central regulators of digestive system physiology and disease. A comprehensive review highlights how these channels convert mechanical forces such as tissue stretching, fluid flow, and pressure into cellular signals that control gastrointestinal motility, secretion, barrier integrity, immune responses, and cancer progression. The findings position Piezo channels as promising biomarkers and therapeutic targets across a broad range of digestive disorders.

A growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized. A recent review proposes that tumors expressing the tuft cell master regulator POU2F3 represent a distinct molecular class of “tuft cell-like” cancers spanning multiple organs, including the lung, pancreas, stomach, colon, breast, prostate, and neuroendocrine tissues. These tumors exhibit unique biological characteristics that may create new opportunities for diagnosis, prognosis, and targeted therapy.

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC). The authors synthesize current knowledge of ferroptosis mechanisms, biomarkers, therapeutic agents, combination strategies, and translational challenges, proposing a framework that links ferroptosis regulatory networks with precision medicine approaches.

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin. A new review highlights autophagy, the natural process by which cells recycle damaged proteins and organelles, as a promising therapeutic target that could improve treatment responses and help overcome resistance to chemotherapy.

Regularly checking in with patients with metastatic breast cancer by way of an app to enquire about their well-being – and responding promptly – can alleviate their debilitating fatigue and make their daily lives easier. This was demonstrated by researchers at Charité – Universitätsmedizin Berlin and the German Cancer Society in a study published today in the journal JAMA Oncology*. The study is the result of the PRO B Innovation Fund project, which was implemented in collaboration with the health insurance providers BARMER, DAK-Gesundheit, and mkk – meine krankenkasse. Based on the positive results, the Federal Joint Committee (G-BA) is recommending to incorporate the new treatment concept into standard care.